CMTM6和CMTM4在肿瘤发生、发展及预后中的作用

doi:10.3760/cma.j.cn371439-20240328-00119

国际肿瘤学杂志 ›› 2024, Vol. 51 ›› Issue (11): 706-711.doi: 10.3760/cma.j.cn371439-20240328-00119

CMTM6和CMTM4在肿瘤发生、发展及预后中的作用

马明珠¹, 高晓玲²()

¹山西医科大学第二临床医学院，太原 030000
²山西医科大学第二医院呼吸与危重症医学科，太原 030000

收稿日期:2024-03-28 修回日期:2024-07-12 出版日期:2024-11-08 发布日期:2024-12-26
通讯作者: 高晓玲 E-mail:937658284@qq.com
基金资助:
国家自然科学基金(82370091);山西省卫生健康委员会科技兴医创新计划(2023XM001);山西省科技成果转化引导专项(202204021301068);山西省高等教育“百亿工程”科技引导专项(BYJL029)

Role of CMTM6 and CMTM4 protein in tumorigenesis， development and prognosis

Ma Mingzhu¹, Gao Xiaoling²()

¹Second Clinical Medical College of Shanxi Medical University， Taiyuan 030000， China
²Department of Respiratory and Critical Care Medicine， Second Hospital of Shanxi Medical University， Taiyuan 030000， China

Received:2024-03-28 Revised:2024-07-12 Online:2024-11-08 Published:2024-12-26
Contact: Gao Xiaoling E-mail:937658284@qq.com
Supported by:
National Natural Science Foundation of China(82370091);Shanxi Provincial Health Commission Science and Technology Innovation Program(2023XM001);Shanxi Provincial Science and Technology Achievement Transformation Guidance Project(202204021301068);Shanxi Provincial Higher Education "Ten Billion Project" Science and Technology Guidance Project(BYJL029)

摘要/Abstract

摘要：

含有MARVEL跨膜结构域的趋化样因子基因（CMTM）家族在肿瘤发生、发展、转移和耐药方面起着至关重要的作用。CMTM6和CMTM4是调节程序性死亡受体配体1（PD-L1）稳定性的关键蛋白，尤其在肿瘤免疫治疗耐药性中发挥着重要作用。目前，CMTM6和CMTM4与肿瘤相关的详尽分子机制尚未完全明确。深入研究CMTM4和CMTM6在肿瘤中的表达、生物学作用以及调控机制将为肿瘤的诊断、治疗以及预测预后等方面提供新的思路和靶点。

关键词: CMTM6, CMTM4, 肿瘤, 耐药性

Abstract:

The CKLF-like MARVEL transmembrane domain containing family of genes （CMTM） family plays a crucial role in tumorigenesis， development， metastasis， and drug resistance. CMTM6 and CMTM4 are key proteins that regulate the stability of programmed death-ligand 1 （PD-L1） and play an important role in tumor immunotherapy resistance in particular. At present， the detailed molecular mechanisms linking CMTM6 and CMTM4 with tumors have not been fully understood. In-depth study of the expression， biological role and regulatory mechanism of CMTM4 and CMTM6 in tumors will provide new ideas and targets for the diagnosis， treatment and prediction of prognosis of tumors.

Key words: CMTM6, CMTM4, Neoplasms, Drug resistance

马明珠, 高晓玲. CMTM6和CMTM4在肿瘤发生、发展及预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(11): 706-711.

Ma Mingzhu, Gao Xiaoling. Role of CMTM6 and CMTM4 protein in tumorigenesis， development and prognosis[J]. Journal of International Oncology, 2024, 51(11): 706-711.

参考文献 65

[1]	Han W, Ding P, Xu M, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation[J]. Genomics, 2003, 81(6): 609-617. DOI: 10.1016/s0888-7543(03)00095-8. pmid: 12782130
[2]	Wang L, Wu C, Zheng Y, et al. Molecular cloning and characterization of chemokine-like factor super family member 1 (CKLFSF1), a novel human gene with at least 23 alternative splicing isoforms in testis tissue[J]. Int J Biochem Cell Biol, 2004, 36(8): 1492-1501. DOI: 10.1016/j.biocel.2003.11.017.
[3]	Shi S, Rui M, Han W, et al. CKLFSF2 is highly expressed in testis and can be secreted into the seminiferous tubules[J]. Int J Biochem Cell Biol, 2005, 37(8): 1633-1640. DOI: 10.1016/j.biocel.2004.04.028.
[4]	Zhong J, Wang Y, Qiu X, et al. Characterization and expression profile of CMTM3/CKLFSF3[J]. J Biochem Mol Biol, 2006, 39(5): 537-545. DOI: 10.5483/BMBRep.2006.39.5.537. pmid: 17002874
[5]	Chrifi I, Louzao-Martinez L, Brandt M, et al. CMTM3 (CKLF-Like marvel transmembrane domain 3) mediates angiogenesis by regula-ting cell surface availability of VE-cadherin in endothelial adherens junctions[J]. Arterioscler Thromb Vasc Biol, 2017, 37(6): 1098-1114. DOI: 10.1161/atvbaha.116.308792. pmid: 28428220
[6]	Mezzadra R, Sun C, Jae LT, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators[J]. Nature, 2017, 549(7670): 106-110. DOI: 10.1038/nature23669.
[7]	Zhang H, Nan X, Li X, et al. CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma[J]. Biochem Biophys Res Commun, 2014, 447(2): 304-310. DOI: 10.1016/j.bbrc.2014.03.158.
[8]	Liu B, Su Y, Li T, et al. CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation[J]. Oncotarget, 2015, 6(38): 41092-41107. DOI: 10.18632/oncotarget.5732. pmid: 26528697
[9]	Shi W, Zhang C, Ning Z, et al. CMTM8 as an LPA1-associated partner mediates lysophosphatidic acid-induced pancreatic cancer metastasis[J]. Ann Transl Med, 2021, 9(1): 42. DOI: 10.21037/ATM-20-1013. pmid: 33553335
[10]	Chen L, Yang QC, Li YC, et al. Targeting CMTM6 suppresses stem cell-like properties and enhances antitumor immunity in head and neck squamous cell carcinoma[J]. Cancer Immunol Res, 2020, 8(2): 179-191. DOI: 10.1158/2326-6066.CIR-19-0394. pmid: 31771985
[11]	Wei L, Wei Q, Yang X, et al. CMTM6 knockdown prevents glioma progression by inactivating the mTOR pathway[J]. Ann Transl Med, 2022, 10(4): 181. DOI: 10.21037/atm-21-6894. pmid: 35280358
[12]	Peng QH, Wang CH, Chen HM, et al. CMTM6 and PD-L1 co-expression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer[J]. J Immunother Cancer, 2021, 9(2): e001638. DOI: 10.1136/jitc-2020-001638.
[13]	Yin B, Ding J, Hu H, et al. Overexpressed CMTM6 improves prognosis and associated with immune infiltrates of ovarian cancer[J]. Front Mol Biosci, 2022, 9: 769032. DOI: 10.3389/fmolb.2022.769032.
[14]	Zhang S, Yan Q, Wei S, et al. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2021, 132(2): 202-209. DOI: 10.1016/j.oooo.2021.02.019.
[15]	Liu LL, Zhang SW, Chao X, et al. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma[J]. Cancer Immunol Immunother, 2021, 70(2): 417-429. DOI: 10.1007/s00262-020-02691-9.
[16]	Wang H, Fan Y, Chen W, et al. Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity[J]. Oncoimmunology, 2022, 11(1): 2011673. DOI: 10.1080/2162402X.2021.2011673.
[17]	Plate M, Li T, Wang Y, et al. Identification and characterization of CMTM4, a novel gene with inhibitory effects on HeLa cell growth through Inducing G₂/M phase accumulation[J]. Mol Cells, 2010, 29(4): 355-361. DOI: 10.1007/s10059-010-0038-7. pmid: 20213316
[18]	Jin MZ, Jin WL. The updated landscape of tumor microenvironment and drug repurposing[J]. Signal Transduct Target Ther, 2020, 5(1): 166. DOI: 10.1038/s41392-020-00280-x.
[19]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674. DOI: 10.1016/j.cell.2011.02.013. pmid: 21376230
[20]	Wang X, Guo G, Guan H, et al. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 87. DOI: 10.1186/s13046-019-1085-3. pmid: 30777100
[21]	Mo L, Chen Q, Zhang X, et al. Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer[J]. Vaccine, 2017, 35(43): 5932-5938. DOI: 10.1016/j.vaccine.2017.08.093. pmid: 28923424
[22]	Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy[J]. Nat Med, 2018, 24(5): 541-550. DOI: 10.1038/s41591-018-0014-x. pmid: 29686425
[23]	Schaaf MB, Garg AD, Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy[J]. Cell Death Dis, 2018, 9(2): 115. DOI: 10.1038/s41419-017-0061-0. pmid: 29371595
[24]	Chen Y, Song Y, Du W, et al. Tumor-associated macrophages: an accomplice in solid tumor progression[J]. J Biomed Sci, 2019, 26(1): 78. DOI: 10.1186/s12929-019-0568-z. pmid: 31629410
[25]	Yaseen MM, Abuharfeil NM, Darmani H. CMTM6 as a master regulator of PD-L1[J]. Cancer Immunol Immunother, 2022, 71(10): 2325-2340. DOI: 10.1007/s00262-022-03171-y. pmid: 35294592
[26]	Zugazagoitia J, Liu Y, Toki M, et al. Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small cell lung cancer[J]. J Thorac Oncol, 2019, 14(12): 2084-2096. DOI: 10.1016/j.jtho.2019.09.014. pmid: 31605795
[27]	Pang X, Wang SS, Zhang M, et al. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway[J]. Cancer Immunol Immunother, 2021, 70(4): 1015-1029. DOI: 10.1007/s00262-020-02741-2. pmid: 33104837
[28]	Wu X, Lan X, Hu W, et al. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer[J]. Cancer Immunol Immunother, 2021, 70(11): 3235-3248. DOI: 10.1007/s00262-021-02931-6. pmid: 33818637
[29]	Baine MJ, Chakraborty S, Smith LM, et al. Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility[J]. PLoS One, 2011, 6(2): e17014. DOI: 10.1371/journal.pone.0017014.
[30]	Liu Y, Guo J, Huang L. Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies[J]. The-ranostics, 2020, 10(7): 3099-3117. DOI: 10.7150/thno.42998.
[31]	Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity[J]. Int J Cancer, 2010, 127(4): 759-767. DOI: 10.1002/ijc.25429. pmid: 20518016
[32]	He J, Miao R, Chen Y, et al. The dual role of regulatory T cells in hepatitis B virus infection and related hepatocellular carcinoma[J]. Immunology, 2024, 171(4): 445-463. DOI: 10.1111/imm.13738.
[33]	Guan X, Zhang C, Zhao J, et al. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas[J]. EBioMedicine, 2018, 35: 233-243. DOI: 10.1016/j.ebiom.2018.08.012. pmid: 30131308
[34]	Schuler G. Dendritic cells in cancer immunotherapy[J]. Eur J Immunol, 2010, 40(8): 2123-2130. DOI: 10.1002/eji.201040630. pmid: 20853498
[35]	Melms JC, Ho P, Rogava M, et al. From patient tissue correlates to molecular mechanisms of cancer immune evasion: the emerging role of CD58 and PD-L1 co-regulation via CMTM6[J]. Genes Immun. 2024, 25(1): 82-84. DOI: 10.1038/s41435-023-00224-9.
[36]	Farhood B, Najafi M, Mortezaee K. CD8⁺ cytotoxic T lymphocytes in cancer immunotherapy: a review[J]. J Cell Physiol, 2019, 234(6): 8509-8521. DOI: 10.1002/jcp.27782. pmid: 30520029
[37]	Koh YW, Han JH, Haam S, et al. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients[J]. Oncoimmunology, 2019, 8(10): e1629261. DOI: 10.1080/2162402X.2019.1629261.
[38]	Shang X, Li J, Wang H, et al. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma[J]. Int Immunopharmacol, 2020, 88: 106864. DOI: 10.1016/j.intimp.2020.106864.
[39]	Wang Z, Peng Z, Liu Q, et al. Co-expression with membrane CMTM6/4 on tumor epithelium enhances the prediction value of PD-L1 on anti-PD-1/L1 therapeutic efficacy in gastric adenocarcinoma[J]. Cancers (Basel), 2021, 13(20): 5175. DOI: 10.3390/cancers13205175.
[40]	Burr ML, Sparbier CE, Chan YC, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity[J]. Nature, 2017, 549(7670): 101-105. DOI: 10.1038/nature23643.
[41]	Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond[J]. Adv Exp Med Biol, 2020, 1248: 33-59. DOI: 10.1007/978-981-15-3266-5_3. pmid: 32185706
[42]	Ruivo CF, Adem B, Silva M, et al. The biology of cancer exosomes: insights and new perspectives[J]. Cancer Res, 2017, 77(23): 6480-6488. DOI: 10.1158/0008-5472.CAN-17-0994. pmid: 29162616
[43]	Morrissey SM, Yan J. Exosomal PD-L1: roles in tumor progression and immunotherapy[J]. Trends Cancer, 2020, 6(7): 550-558. DOI: 10.1016/j.trecan.2020.03.002. pmid: 32610067
[44]	Zhu X, Zhang S, Tan S, et al. Expression of CMTM4 shows clinical significance in lung cancer[J]. Transl Cancer Res, 2020, 9(10): 6214-6220. DOI: 10.21037/tcr-20-1254. pmid: 35117232
[45]	Chui NN, Cheu JW, Yuen VW, et al. Inhibition of CMTM4 sensitizes cholangiocarcinoma and hepatocellular carcinoma to T cell-mediated antitumor immunity through PD-L1[J]. Hepatol Commun, 2022, 6(1): 178-193. DOI: 10.1002/hep4.1682.
[46]	Tan S, Guo X, Bei C, et al. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma[J]. BMC Cancer, 2022, 22(1): 905. DOI: 10.1186/s12885-022-09999-y. pmid: 35986302
[47]	Bei C, Zhang Y, Wei R, et al. Clinical significance of CMTM4 expression in hepatocellular carcinoma[J]. Onco Targets Ther, 2017, 10: 5439-5443. DOI: 10.2147/OTT.S149786.
[48]	Zhou HQ, Li JH, Liu LW, et al. Increased CMTM4 mRNA expression predicts a poor prognosis in patients with hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(6): 596-601. DOI: 10.1016/j.hbpd.2020.06.004.
[49]	Xue H, Li T, Wang P, et al. CMTM4 inhibits cell proliferation and migration via AKT, ERK1/2, and STAT3 pathway in colorectal cancer[J]. Acta Biochim Biophys Sin (Shanghai), 2019, 51(9): 915-924. DOI: 10.1093/abbs/gmz084.
[50]	Li T, Cheng Y, Wang P, et al. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma[J]. J Exp Clin Cancer Res, 2015, 34: 122. DOI: 10.1186/s13046-015-0236-4. pmid: 26474560
[51]	Miao B, Hu Z, Mezzadra R, et al. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1[J]. Cancer Cell, 2023, 41(10): 1817-1828.e9. DOI: 10.1016/j.ccell.2023.08.008.
[52]	Li M, Guo H, Wang Q, et al. Pancreatic stellate cells derived exosomal miR-5703 promotes pancreatic cancer by downregulating CMTM4 and activating PI3K/Akt pathway[J]. Cancer Lett, 2020, 490: 20-30. DOI: 10.1016/j.canlet.2020.06.009. pmid: 32585413
[53]	Wu F, Yang J, Shang G, et al. Exosomal miR-224-5p from colorectal cancer cells promotes malignant transformation of human normal colon epithelial cells by promoting cell proliferation through downregulation of CMTM4[J]. Oxid Med Cell Longev, 2022, 2022: 5983629. DOI: 10.1155/2022/5983629.
[54]	Zhang H, Zhang X, Yuan X, et al. MicroRNA-205 inhibits renal cells apoptosis via targeting CMTM4[J]. Iran J Basic Med Sci, 2015, 18(10): 1020-1026. DOI: 10.22038/IJBMS.2015.5467. pmid: 26730338
[55]	Zhao W, Zhao F, Yang K, et al. An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade[J]. J Cell Biochem, 2019, 120(8): 13330-13341. DOI: 10.1002/jcb.28607. pmid: 30916827
[56]	Mohapatra P, Shriwas O, Mohanty S, et al. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis[J]. JCI Insight, 2021, 6(4): 143643. DOI: 10.1172/jci.insight.143643.
[57]	Xing F, Gao H, Chen G, et al. CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer[J]. Mol Cancer, 2023, 22(1): 6. DOI: 10.1186/s12943-023-01716-y. pmid: 36627608
[58]	Mohapatra P, Mohanty S, Ansari SA, et al. CMTM6 attenuates cisplatin-induced cell death in OSCC by regulating AKT/c-Myc-driven ribosome biogenesis[J]. FASEB J, 2022, 36(10): e22566. DOI: 10.1096/fj.202200808RR.
[59]	Huang X, Liu W, Liu C, et al. CMTM6 as a candidate risk gene for cervical cancer: comprehensive bioinformatics study[J]. Front Mol Biosci, 2022, 9: 983410. DOI: 10.3389/fmolb.2022.983410.
[60]	Huang X, Xiang L, Wang B, et al. CMTM6 promotes migration, invasion, and EMT by interacting with and stabilizing vimentin in hepatocellular carcinoma cells[J]. J Transl Med, 2021, 19(1): 120. DOI: 10.1186/s12967-021-02787-5. pmid: 33757532
[61]	Ho P, Melms JC, Rogava M, et al. The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity[J]. Cancer Cell, 2023, 41(7): 1207-1221.e12. DOI: 10.1016/j.ccell.2023.05.014. pmid: 37327789
[62]	Huang Y, Zhu Y, Yang J, et al. CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma[J]. Cell Death Dis, 2022, 13(3): 251. DOI: 10.1038/s41419-022-04676-1. pmid: 35304440
[63]	Peng QH, Wang CH, Chen HM, et al. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer[J]. J Immunother Cancer, 2021, 9(2): e001638. DOI: 10.1136/jitc-2020-001638.
[64]	Liang HY, Chen SL, Cai SH, et al. CMTM6 recruits T cells within the endocervical adenocarcinoma microenvironment and suppresses cell proliferation via the p53 pathway[J]. J Med Virol, 2023, 95(3): e28605. DOI: 10.1002/jmv.28605.
[65]	Shi S, Ma HY, Sang YZ, et al. CMTM6 expression and clinical significance of and in triple-negative breast cancer[J]. Biomed Res Int, 2022, 2022: 8118909. DOI: 10.1155/2022/8118909.

CMTM6和CMTM4在肿瘤发生、发展及预后中的作用

Role of CMTM6 and CMTM4 protein in tumorigenesis， development and prognosis

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 65

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韦伟, 蔡曌颖, 钱亚云. 通关藤联合XELOX方案促进人结直肠癌HCT116细胞双硫死亡的作用[J]. 国际肿瘤学杂志, 2024, 51(9): 545-555.
[2]	袁胜芳, 任婕, 林卫佳, 姬泽萱, 张长洪, 王布. EGFR共突变状态对晚期肺腺癌患者预后的价值研究[J]. 国际肿瘤学杂志, 2024, 51(9): 556-562.
[3]	尹浩, 吴旭栋, 王磊. 螺旋断层放疗治疗食管癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(9): 578-584.
[4]	施学兵, 吴静, 邓文霞. Vav3与恶性肿瘤的关系[J]. 国际肿瘤学杂志, 2024, 51(9): 585-589.
[5]	韩晓旭, 张楠, 刘帅. 孕烷X受体在乳腺癌耐药中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 590-594.
[6]	伍杨, 李甜, 张润兵, 史婷婷, 高春, 郑晓凤, 张久聪. 胃癌及食管胃结合部癌免疫及靶向治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 595-600.
[7]	詹海峰, 王文学, 耿嘉蔚. 晚期结直肠癌精准分子靶向治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 601-605.
[8]	郭玮, 王冬慧, 王振华, 薛昭君. 晚期肿瘤患者PD-1单抗治疗后免疫相关甲状腺功能异常与生存情况的相关性[J]. 国际肿瘤学杂志, 2024, 51(8): 481-486.
[9]	刘文会, 殷平, 戚洁. 血清G-17、sB7-H3、DKK1检测对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(8): 498-503.
[10]	王燕. 经阴道超声弹性成像联合血清miR-144-3p、CMTM6在宫颈癌前病变和宫颈癌中的鉴别诊断价值[J]. 国际肿瘤学杂志, 2024, 51(8): 504-509.
[11]	王秋实, 徐瑞涛, 李松, 褚佳慧, 刘联. 免疫检查点抑制剂相关多器官不良反应研究进展[J]. 国际肿瘤学杂志, 2024, 51(8): 510-514.
[12]	李志伟, 翟春宝. 中药多酚类成分抗结直肠癌作用研究进展[J]. 国际肿瘤学杂志, 2024, 51(8): 526-531.
[13]	彭丹, 吕璐, 孙鹏飞. 影像组学在宫颈癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(8): 532-537.
[14]	孟繁明. 伊尼妥单抗联合卡培他滨治疗曲妥珠单抗经治的HER2阳性晚期乳腺癌1例[J]. 国际肿瘤学杂志, 2024, 51(8): 538-541.
[15]	Saber Amin, Chi Lin. 质子束放疗在中枢神经系统肿瘤患者中的应用趋势：美国国家癌症数据库分析（2004—2021年）[J]. 国际肿瘤学杂志, 2024, 51(7): 424-431.